Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen names former Sanofi chief as new CEO, shares rise
08:08am, Thursday, 10'th Nov 2022
Biogen Inc. BIIB, -1.35% stock rose 1% in premarket trades on Thursday after Christopher A. Viehbacher was named president and chief executive officer and a member of the board, effective Nov. 14.
BIIB vs. RGEN: Which Stock Is the Better Value Option?
12:49pm, Monday, 07'th Nov 2022
BIIB vs. RGEN: Which Stock Is the Better Value Option?
Is Biogen Poised for a Bull Run?
09:30am, Thursday, 03'rd Nov 2022
Biogen has been a market-beating stock this year, but can that trend continue?
Trading Ideas On The Upcoming CTAD 2022 Conference
03:27pm, Wednesday, 02'nd Nov 2022
The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie
Biogen: Second Time's A Charm
12:37am, Tuesday, 01'st Nov 2022
Biogen appears set to obtain approval of a 2nd Alzheimer's drug. Lecanemab is far better received by the market with total peak sales forecasted at up to $14 billion with Biogen sharing 50% of the pro
Deal Activity Could Jumpstart Biotechnology
11:35pm, Monday, 31'st Oct 2022
Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID
Biogen: Super-Strong Momentum In A Defensive Sector
02:51pm, Monday, 31'st Oct 2022
Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. The latest positive readout on LECANEMAB, its second Alzheimer's drug likely to get FDA
10 Stocks Turned $10,000 To $190,479 In 10 Months
08:00am, Monday, 31'st Oct 2022
Investors finally got a decent month in the S&P 500. And some really maximized their gains.
Don't Get Used to Lower Medicare Part B Premiums -- Here's Why
05:30am, Saturday, 29'th Oct 2022
Medicare might have to begin paying billions of extra dollars for new drugs in the not-too-distant future.
Is Biogen a Buy After It Boosted Guidance?
05:52am, Wednesday, 26'th Oct 2022
There's a much bigger story for this biotech than its improved 2022 outlook.
Biogen Lifts Profit Estimates as Investors Look to Alzheimer's Drug
03:40pm, Tuesday, 25'th Oct 2022
The biotech raised its earnings per share estimate to $16.50 to $17.15 from the previously estimated $15.25 to $16.75 range.
Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook
03:03pm, Tuesday, 25'th Oct 2022
Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.
Biogen and Eisai make plans to take another Alzheimer's drug to the FDA
02:26pm, Tuesday, 25'th Oct 2022
Biogen Inc. BIIB, -2.03% and Eisai Co. Ltd. 4523, +3.57% are getting closer to possible approval of their new treatment for Alzheimer's disease, with plans to submit the drug for full Food and Drug Ad
Biogen Inc. (BIIB) Q3 2022 Earnings Call Transcript
09:57am, Tuesday, 25'th Oct 2022
Biogen Inc. (NASDAQ:BIIB ) Q3 2022 Earnings Conference Call October 25, 2022 8:00 AM ET Company Participants Mike Hencke - Head, Investor Relations Michel Vounatsos - Chief Executive Officer Priya Sin
Biogen Inc. (BIIB) Surpasses Q3 Earnings and Revenue Estimates
09:47am, Tuesday, 25'th Oct 2022
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.50% and 1.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
